about
Opportunities for improving triple‐negative breast cancer outcomes: results of a population‐based studyGermline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer.Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.Predictive Factors for BRCA1 and BRCA2 Genetic Testing in an Asian Clinic-Based Population.High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.Intrafamilial disclosure of risk for hereditary breast and ovarian cancer: points to considerTriple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia.Systemic therapy options in BRCA mutation-associated breast cancer.Triple-negative breast cancer: investigating potential molecular therapeutic target.Hereditary breast cancer syndromes and genetic testing.Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.A fragmented alignment method detects a putative phosphorylation site and a putative BRC repeat in the Drosophila melanogaster BRCA2 protein.Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.Morphometric analysis of a triple negative breast cancer cell line in hydrogel and monolayer culture environments.CD74: a potential novel target for triple-negative breast cancer.
P2860
Q29248325-B77EAD84-2A0E-49C1-B5C3-620E1C7C6FD7Q34228853-9912721F-7C80-4452-8B0E-167A311CC3F1Q34460831-CF51D16E-F65B-4532-B361-44C998E476A0Q34489002-FD2169BF-4F5C-4DDD-99CB-D523186DB582Q35722508-FB2CC387-D8EE-4B22-9685-1DBE53D7F896Q36110709-7B46AFB3-9D98-4CB1-B87F-928B25C68027Q36884609-5D7109E9-3705-43C7-AA05-CA5A0DFCD5F7Q37652666-6DE6EB91-763A-4606-9852-2A6F90C34706Q38025991-37F5D810-6FD7-45ED-8C2D-DBFE7313FACCQ38259322-0ADF8AD7-895C-4B60-A07C-4FB98C190058Q38266306-A2FE9EDD-12F2-48F2-8F6C-AD37CC20A0E7Q41740523-D1E5F049-B1B1-44DE-98B1-5596C055261BQ41956394-A9BEC0B8-F162-4F05-AE23-59481B4003A8Q42491917-9497B182-8A7C-4C2A-834A-6B1654EB0CF1Q50268380-AAA9CDBF-2E4D-404D-842E-116F70730B39Q54486945-7D8A3357-9811-40EE-A95C-2144D9CAFA24
P2860
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
BRCA2 mutations and triple-negative breast cancer
@ast
BRCA2 mutations and triple-negative breast cancer
@en
BRCA2 mutations and triple-negative breast cancer
@nl
type
label
BRCA2 mutations and triple-negative breast cancer
@ast
BRCA2 mutations and triple-negative breast cancer
@en
BRCA2 mutations and triple-negative breast cancer
@nl
prefLabel
BRCA2 mutations and triple-negative breast cancer
@ast
BRCA2 mutations and triple-negative breast cancer
@en
BRCA2 mutations and triple-negative breast cancer
@nl
P2860
P50
P1433
P1476
BRCA2 mutations and triple-negative breast cancer
@en
P2093
Katharina Landgraf
Peter Meyer
P2860
P304
P356
10.1371/JOURNAL.PONE.0038361
P407
P577
2012-05-30T00:00:00Z